Clinical Trial Update: Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin mesylate as second-line therapy for locally advanced, unresectable, or metastatic pancreatic cancer; the study is completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Halaven (eribulin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Pancreas, Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-12-09